- ISIN
- US75989R1077
- CUSIP
- 75989R107
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Aug 26, 2021
Highlights
- Market Cap
- $35.67M
- Enterprise Value
- $23.39M
- EPS (TTM)
- -$0.33
- Total Revenue (TTM)
- $1.49M
- Gross Profit (TTM)
- $1.17M
- EBITDA (TTM)
- -$12.58M
- Year Range
- $0.70 - $1.45
- ROA (TTM)
- -87.86%
- ROE (TTM)
- -108.91%
- Avg. Volume (1M)
- 200K
- Avg. Volume Value (1M)
- $183.08K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RNXT Performance Chart
RenovoRx, Inc. (RNXT) is up 14.1% since the beginning of the year. At $1 per share, RNXT is trading 33.9% below its 52-week high of $1.
Loading charts...
Compare this symbol against anything
Returns By Period
RenovoRx, Inc. (RNXT) has returned 14.07% so far this year and -20.80% over the past 12 months.
RenovoRx, Inc.
- 1D
- 1.82%
- 1M
- 4.15%
- 6M
- -7.86%
- YTD
- 14.07%
- 1Y
- -20.80%
- 3Y*
- -21.88%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -35.39%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
RNXT Monthly Returns History
Based on dividend-adjusted daily data since Aug 26, 2021, RNXT's average daily return is +0.05%, while the average monthly return is +1.19%. At this rate, an investment would double in approximately 4.9 years.
Historically, 40% of months were positive and 60% were negative. The best month was Dec 2023 with a return of +257.8%, while the worst month was Nov 2023 at -43.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.
On a daily basis, RNXT closed higher 44% of trading days. The best single day was Aug 30, 2021 with a return of +107.8%, while the worst single day was Aug 31, 2021 at -37.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 23.79% | -15.10% | 14.38% | -15.84% | 6.99% | 7.76% | -2.21% | 14.07% | |||||
| 2025 | 5.43% | -26.48% | -0.99% | -3.03% | 45.83% | -6.07% | -5.70% | -22.58% | 32.29% | -12.60% | -17.35% | -8.43% | -34.88% |
| 2024 | -34.50% | 14.67% | -22.09% | -9.70% | -4.13% | -2.59% | 6.19% | -15.00% | 3.92% | -5.85% | 27.25% | 1.57% | -43.67% |
| 2023 | 11.91% | 76.81% | -25.05% | -10.19% | -40.58% | 21.51% | -12.39% | -18.18% | -17.90% | -14.29% | -43.86% | 257.81% | -2.55% |
| 2022 | -31.40% | 1.20% | -12.80% | -43.00% | 17.37% | 1.02% | -1.79% | 8.00% | -3.81% | -13.37% | 11.43% | 20.51% | -51.45% |
| 2021 | 21.09% | -39.54% | -14.24% | 36.68% | -31.64% | -41.33% |
Benchmark Metrics
RenovoRx, Inc. has an annualized alpha of 2.64%, beta of 0.93, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since August 26, 2021.
- This stock participated in 143.96% of S&P 500 Index downside but only -36.73% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 2.64%
- Beta
- 0.93
- R²
- 0.02
- Upside Capture
- -36.73%
- Downside Capture
- 143.96%
Return for Risk
Risk / Return Rank
RNXT ranks 31 for risk / return — above 31% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for RenovoRx, Inc. (RNXT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RNXT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.70 | ||
| Sortino ratioReturn per unit of downside risk | -1.85 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 1.25 | -0.24 |
| Calmar ratioReturn relative to maximum drawdown | -0.50 | 2.00 | -2.51 |
| Martin ratioReturn relative to average drawdown | -0.81 | 8.49 | -9.31 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the RenovoRx, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the RenovoRx, Inc. was 96.25%, occurring on Nov 17, 2023. The portfolio has not yet recovered.
The current RenovoRx, Inc. drawdown is 94.02%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-96.25%Nov 2023 | 2y 2mo | — | 4y 11moAug 2021 - now | — |
-12.00%Aug 2021 | 1d | 4d | 4dAug 2021 - Aug 2021 | — |
Drawdown Indicators
| RNXT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.25% | -56.78% | -39.47% |
Max Drawdown (1Y)Largest decline over 1 year | -45.34% | -9.10% | -36.24% |
Max Drawdown (3Y)Largest decline over 3 years | -72.85% | -18.90% | -53.95% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -94.02% | -1.58% | -92.44% |
Average DrawdownAverage peak-to-trough decline | -87.52% | -10.70% | -76.82% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 27.93% | 2.14% | +25.79% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of RenovoRx, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how RenovoRx, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for RNXT relative to other companies in the Biotechnology industry. Currently, RNXT has a P/S ratio of 23.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for RNXT in comparison with other companies in the Biotechnology industry. Currently, RNXT has a P/B value of 3.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with RNXT
Add RenovoRx, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RNXT